FeesSafety
Pluang+

Failed Venezuelan oil deal cost Poland $230M, mostly via USDt stablecoin, but yielded only $29M in oil.

Market News
17 Sep 2026
Crypto Economy
View Source
Bearish
Failed Venezuelan oil deal cost Poland $230M, mostly via USDt stablecoin, but yielded only $29M in oil.

Poland's Orlen advanced $230 million in a failed Venezuelan oil deal, with most funds transferred using the USDt stablecoin. Despite the large payment, only about $29 million worth of oil was delivered, highlighting risks in using stablecoins for international trade. This case raises concerns about transparency and security in crypto-based transactions for large-scale commodity deals.

The story about Stable.com's expansion with Polygon for direct-to-bank transfers using USDT or PYUSD is presented with Pluang's market context. For readers following cryptocurrency markets, here is Pluang's snapshot as of Sep 17, 2026 22:52 WIB: 46 out of 50 major cryptocurrencies rose today. Notable movers include BAL at Rp16.297 with an 11.14% increase, CAKE at Rp43.035 rising 9.96%, and SUSHI at Rp3.934 up 9.86%.

More News

CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...

Market News
Bullish
1 hour ago
CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma

CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma

The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...

Market News
Bullish
1 hour ago
CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...

Market News
Bullish
1 hour ago
Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia

Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia

Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...

Market News
Bullish
2 hours ago
Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia

Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia

Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App